DOCSLIB.ORG

United States Patent Office Patented Feb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent Office Patented Feb 3,565,778 United States Patent Office Patented Feb. 23, 1971 1. 2 ing with a trialkylstannane an a,6-oxido-steroid-ketone in 3,565,778 PROCESS FOR THE MANUFACTURE OF a Suitable solvent, while being irradiated with ultraviolet g-HYDROXY-STEROID-KETONES light. The invention also comprises new 6-hydroxysteroid Oskar Jeger, Zollikerberg, Zurich, Hans Ueli Wehrli, ketones of the o- or 3-androstane series preparable by Schaffhausen, and Kurt Schaffner, Zurich, Switzerland, the new process, and pharmaceutical preparations con assignors to Ciba Corporation, New York, N.Y., a cor taining them. The new compounds display androgenic or poration of Delaware anti-androgenic activity. No Drawing. Filed July 9, 1968, Ser. No. 743,278 Claims priority, application Switzerland, July 13, 1967, DESCRIPTION OF THE PREFERRED . 10,108/67 EMBODIMENTS Int. CI. B01j I/10 O U.S. Cl. 204-158 12 Claims In the hydroxy-steroid-ketones obtainable with the new process of the invention the ketone group may be in the steroid ring system or in a side chain, and any desired ABSTRACT OF THE DISCLOSURE configuration is possible at the various carbon atoms, o,6-Oxido-steroid-ketones are converted into 3-hydroxy 15 especially also at those to which the hydroxyl group is ketones according to the partial formulae scheme attached. In this context the term steroid-ketones refers to any desired derivative of the cyclopentano-polyhydro -C-C-C-() (8) - - -c-bH-C- phenanthrenes, that is to say not only to the normal (Alk)3SnH. & 20 Steroids but, for example, also to 18- and 19-nor-steroids, O O O CH A-homo-, B-homo-, A-nor-, B-nor-, C-nor- or D-homo when they are treated with tri-n-butylstannane in an or steroids. ganic solvent while irradiating with ultraviolet light. New The steroid starting material used in the new process types of 5-hydroxy-steroid-ketones are inter alia 17-oxy may be any o,6-oxido-steroid-ketone, for example of the genated - 7 - methyl-5-hydroxy-3-oxo-androstanes and 19 25 androstane, pregnane, cholane, cholestane, spirostane, nor-androstanes, especially the 7cy-methyl-derivatives and cardanolide or furoStane series, for instance 4,5-oxido-3- corresponding A-steroids without the 7-methyl group. OXO - Steroids, 1,2-oxido-3-oxo-steroids, 4,5-oxido-6-oxo steroids, 5,6-oxido-7-oxo-steroids, 9,11-oxido-12-oxo-ste roids, 9,10-oxido-1 1-oxo-steroids or 3,4-oxido-2-oxo-ste BACKGROUND OF THE INVENTION 30 roids, which may contain in other free positions of the oxo-steroids, 4,5-oxido-6-oxo-steroids, 5,6-oxido-7-oxo-ste There are already known (3-hydroxy-steroid-ketones of roids, 9, 11 - oxido-12-oxo-steroids, 9,10-oxido-11-oxo-ste the various steroid series with the functional groups in roids or 3,4-oxido-2-oxo-steroids, which may contain in various positions of the cyclopentano-polyhydrophenan other free positions of the steroid skeleton further sub threne or in the side chains, for example, in the pregnane stituents, and in the rings and/or possibly in the side 17g side chain. Thus, inter alia in German specification chains, they may contain double bonds. No. 960,200, A-16-hydroxy-3,20-diones, containing a free The starting materials are known or can be manufac or esterified 21-hydroxyl groups have been described. tured in known manner. For example, ox,6-oxido-steroid These compounds are pharmacologically active and act ketones are preferably manufactured by expoxidation of as Suprarenal hormones. French Pat. 1,463,849 discloses 40 the corresponding unsaturated ketones by treatment with 5-hydroxy-3-oxosteroids of the androstane and pregnane hydrogen peroxied in the presence of sodium hydroxide Series which are suitable for use as starting materials for solution or by means of an organic per-acid, such as the process, claimed in that French specification, for the perphthalic or perbenzoic acid. manufacture of 5,10-secosteroids. 1-hydroxy-3-oxosteroids The treatment according to this invention with a tri of the pregnane series, especially the 10-hydroxy deriva 45 alkylstannane with irradiation is carried out in an inert tive of cortisone which has a much higher anti-inflam solvent that is stable towards the trialkylstannane and matory effect than cortisone, have been mentioned for towards the ultraviolet light used for the irradiation, if instance in Japanese Pat. 22, 142, and 10-hydroxy-deriva desired or required with addition of a sensitizer. tives of the 5ck-androstane series having a good anabolic Preferred solvents are aliphatic, cycloaliphatic or aro androgenic activity in South African Pat. 63/5,165, and 50 matic hydrocarbons, especially benzene. analogous compounds of the 5p3-androstane series, which As sensitizers there may be used those which are gen likewise have a good anabolic-androgenic activity, in erally employed in photoinduced reactions, for example Dutch patent application No. 6,501,292/.65. The known triphenylene. methods for the manufacture of such hydroxy-steroid A suitable source of light for the irradiation accord ketones vary from case to case; thus, the pregnane com 55 ing to this invention is artificial or natural ultraviolet light, pounds described in the aforementioned German patent preferably ultraviolet light as emitted by mercury high are obtained by adding an arylcarbinol on to the 16, 17 pressure burners. The irradiation is preferably performed double bond of 16,17-unsaturated pregnanes and reduc at room temperature. tive splitting of the 16-aryloxy group formed. In the case Preferred trialkylstannanes are tri-lower alkylstannanes, of the above-mentioned French patent 4,5-oxido-3-ketones 60 above all tri-n-butylstannane. are temporarily ketalized and then reduced to 5-hydroxy Some of the process products are known and, as men compounds with a complex light metal hydride. The 1 tioned above, they may be used as intermediates in the hydroxy-3-oxo-androstane compounds of the said South manufacture of pharmacologically active compounds or African patent are likewise obtained by splitting an oxido they possess as such pharmacological properties. 3-ketone, namely the epoxide group of a 1,2-oxido-3- 65 The present invention further includes new 6-hydroxy ketone, but in this case the reduction is carried out with steroid-ketones, in fact 17-oxygenated 7-methyl-5-hydroxy an alkali or alkaline earth metal in liquid ammonia or in 3-oxo-androstanes and 19-nor-androstanes, especially 7 oz an amine. methyl derivatives of this type; also 17-oxygenated A-5- SUMMARY OF THE INVENTION 70 hydroxy-3-oxo-androstenes and 19-nor-androstenes, espe The invention provides a new general method for the cially also their 7-methyl derivatives; and 17-oxygenated marufacture of B-hydroxy-steroids which consists in treat 56-hydroxy-3-oxo-19-nor-androstanes. 3,565,778 3 4. This group of new compounds are thus 17-oxygenated androstenes said above, thus the 17-oxygenated A-10,2a 5-hydroxy-3-oxo-compounds of the 5a- and 56-androstane oxido-3-oxo-androstene and -19-nor-androstene com and 19-nor-androstane series, which compounds are char pounds, for example A-10,2a-oxido-17 3-hydroxy-andro acterized by the presence of at least one of the following sten-3-one and its esters, such as the 17-acetate, and A features: the 1,2-double bond, a 7-methyl group, or the 10,2a-oxido-176-hydroxy-19-nor-androsten-3-one and its (3-configuration at C5 together with the 19-nor-structure. 17-esters, such as the 17(3-acetate. In these compounds the substituent in position 17 is, The invention includes also any variant of the process for example, either an oxo group or a free, etherified or in which an intermediate obtained at any stage is used esterified hydroxyl group together with a hydrogen atom as starting material and any remaining step/steps is/are or with an unsubstituted or substituted, saturated or un carried out, or the process is discontinued at any stage saturated lower aliphatic hydrocarbon residue. O thereof, or in which a starting material is formed under An esterified hydroxyl group is above all one derived the reaction conditions. from an organic carboxylic acid of the aliphatic, alicyclic, The invention includes also the manufacture of pharma aromatic or heterocyclic series, especially one that con ceutical preparations for use in human or veterinary tains 1 to 18 carbon atoms, for example formic, acetic, medicine, which contain the new pharmacologically active propionic acid, a butyric acid, a valeric such as n-valeric substances of the present invention described above as acid, or trimethylacetic, trifluoroacetic acid, a caproic acid active ingredients, in conjunction or admixture with a such as B-trimethylpropionic acid or diethylacetic acid, pharmaceutical excipient. The excipient used may be an Oenanthic, caprylic, pelargonic, capric acid and unde organic or inorganic substance suitable for enteral, for cyclic acid, for example, undecylenic acid, lauric, myristic, 20 example oral, parenteral or local administration. Suitable palmitic or stearic acids, for example oleic acid, cyclo excipients are substances that do not react with the new propane-, cyclopentane-, and cyclohexane-carboxylic acid, compounds, for example water, gelatin, lactose, starches, cyclopropylmethanecarboxylic, cyclobutylmethanecarbox magnesium stearate, talcum, vegetable oils, benzyl alco ylic, cyclopentylethanecarboxylic, cyclohexylethanecar hols, gums, polyalkyleneglycols, white petroleum jelly, boxylic acid, cyclopentyl- cyclohexyl- or phenyl-acetic or cholesterol or other known medicinal excipients. The -propionic acids, benzoic, phenoxyalkanoic acids such as pharmaceutical preparations may be in solid form, for ex phenoxyacetic acid, dicarboxylic acids such as succinic ample tablets, dragees or capsules, or in liquid or semi acid, phthalic, quinolic acid, furan-2-carboxylic, 5-tertiary liquid form solutions, suspensions, emulsions, ointments butyl-furan-2-carboxylic, 5-bromofuran-2-carboxylic acid, or creams.
Load more

Recommended publications
  • Seco-Steroids C07C)
    CPC - C07J - 2021.08 C07J STEROIDS (seco-steroids C07C) Definition statement This place covers: Compounds containing a cyclopenta[a]hydrophenanthrene skeleton (see below) or a ring structure derived therefrom: • by contraction or expansion of one ring by one or two atoms; • by contraction or expansion of two rings each by one atom; • by contraction of one ring by one atom and expansion of one ring by one atom; • by substitution of one or two carbon atoms of the cyclopenta[a]hydrophenanthrene skeleton, which are not shared by rings, by hetero atoms, in combination with the above defined contraction or expansion or not, or; • by condensation with carbocyclic or heterocyclic rings in combination with one or more of the foregoing alterations or not. Preparation of steroids including purification, separation, stabilisation or use of additives unless provided for elsewhere, as specified below. Treatment and modification of steroids provided that • the treatment is not provided for elsewhere and • the resultant product is a compound under the subclass definition. Relationships with other classification places In class C07, in the absence of an indication to the contrary, a compound is classified in the last appropriate place, i.e. in the last appropriate subclass. For example cyclopenta [a] hydrophenantrenes are classified in subclass C07J as steroids and not in subclasses C07C or C07D as carbocyclic or heterocyclic compounds. Subclass C07J is a function-oriented entry for the compounds themselves and does not cover the application or use of the compounds under the subclass definition. For classifying such information other entries in the IPC exist, for example: Subclass A01N: Preservation of bodies of humans or animals or plants or parts thereof; biocides, e.g.
    [Show full text]
  • Three-Dimensional Structure of Holo 3A,20J3-Hydroxysteroid
    Proc. Nati. Acad. Sci. USA Vol. 88, pp. 10064-10068, November 1991 Biochemistry Three-dimensional structure of holo 3a,20j3-hydroxysteroid dehydrogenase: A member of a short-chain dehydrogenase family (x-ray crystaflography/steroid-metabolizing enzyme/dinucleotide-linked oxldoreductase/sterold-protein interaction/sequence and folding homologies) DEBASHIS GHOSH*t, CHARLES M. WEEKS*, PAWEL GROCHULSKI*t, WILLIAM L. DUAX*, MARY ERMAN*, ROBERT L. RIMSAY§, AND J. C. ORR§ *Medical Foundation of Buffalo, 73 High Street, Buffalo, NY 14203; and Memorial University of Newfoundland, St. John's, Newfoundland, Canada AlB 3V6 Communicated by Herbert A. Hauptman, July 18, 1991 (receivedfor review May 14, 1991) ABSTRACT The x-ray structure of a short-chain dehy- the substrate binding regions, offers further insight concern- drogenase, the bacterial holo 3a,20/3-hydroxysteroid dehydro- ing the significance of conserved residues and their possible genase (EC 1.1.1.53), is described at 2.6 A resolution. This roles in substrate specificity and overall enzyme function. enzyme is active as a tetramer and crystallizes with four identical subunits in the asymmetric unit. It has the a/( fold characteristic ofthe dinucleotide binding region. The fold ofthe MATERIALS AND METHODS rest of the subunit, the quarternary structure, and the nature The crystals, grown in the presence of 4 mM NADH, belong ofthe cofactor-enzyme interactions are, however, significantly to the space group P43212 having unit cell dimensions a = different from those observed in the long-chain dehydrogena- 106.2 A and c = 203.8 A and contain one full tetramer (106 ses. The architecture of the postulated active site is consistent kDa) in the asymmetric unit (13).
    [Show full text]
  • Proceedings of the Thirtieth Annual Meeting of the American Society for Clinical Investigation Held in Atlantic City, N
    PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 J Clin Invest. 1938;17(4):501-537. https://doi.org/10.1172/JCI100977. Research Article Find the latest version: https://jci.me/100977/pdf PROCEEDINGS OF THE THIRTIETH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL INVESTIGATION HELD IN ATLANTIC CITY, N. J., MAY 2, 1938 READ BEFORE THE SCIENTIFIC SESSION The Successful Treatment of Pernicious Anemia by in powdered form hemostasis was readily obtained in Means of Non-Autolyzed Yeast. By MAXWELL M. hemorrhages following nine dental extractions and three WINTROBE, Baltimore, Md. external wounds in five hemophilic subjects. When ap- It has been the general opinion that yeast, if it pos- plied in liquid form as other hemostatics are usually em- sesses any antianemic potency whatever, is effective only 1 loyed the results were unsatisfactory. Since the co- after autolysis and then only by virtue of its content of agulation time of the circulating blood was unchanged the "extrinsic factor." The observations reported contradict effectiveness of powdered beef globulin substance when this view and indicate that dehydrated yeast which has locally applied to a bleeding wound in hemophilia is not been subjected to autolysis, contains an antiper- attributed to the rapid formation of a firm fibrin clot. nicious anemia substance. Yeast obtained from two dif- The failure of liquid preparations may be due to the ferent sources was effective in the treatment of classical inability to maintain a sufficient concentration of the cases of pernicious anemia.
    [Show full text]
  • 1970Qureshiocr.Pdf (10.44Mb)
    STUDY INVOLVING METABOLISM OF 17-KETOSTEROIDS AND 17-HYDROXYCORTICOSTEROIDS OF HEALTHY YOUNG MEN DURING AMBULATION AND RECUMBENCY A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN NUTRITION IN THE GRADUATE DIVISION OF THE TEXAS WOI\IIAN 'S UNIVERSITY COLLEGE OF HOUSEHOLD ARTS AND SCIENCES BY SANOBER QURESHI I B .Sc. I M.S. DENTON I TEXAS MAY I 1970 ACKNOWLEDGMENTS The author wishes to express her sincere gratitude to those who assisted her with her research problem and with the preparation of this dissertation. To Dr. Pauline Beery Mack, Director of the Texas Woman's University Research Institute, for her invaluable assistance and gui­ dance during the author's entire graduate program, and for help in the preparation of this dissertation; To the National Aeronautics and Space Administration for their support of the research project of which the author's study is a part; To Dr. Elsa A. Dozier for directing the author's s tucly during 1969, and to Dr. Kathryn Montgomery beginning in early 1970, for serving as the immeclia te director of the author while she was working on the completion of the investic;ation and the preparation of this dis- sertation; To Dr. Jessie Bateman, Dean of the College of Household Arts and Sciences, for her assistance in all aspects of the author's graduate program; iii To Dr. Ralph Pyke and Mr. Walter Gilchrist 1 for their ass is­ tance and generous kindness while the author's research program was in progress; To Mr. Eugene Van Hooser 1 for help during various parts of her research program; To Dr.
    [Show full text]
  • The Effects of Exogenous ACTH on 5-3B-Hydroxysteroid Dehydrogenase Activity in the Embryonic Avian Adrenal Gland
    Loyola University Chicago Loyola eCommons Master's Theses Theses and Dissertations 1968 The Effects of Exogenous ACTH on 5-3b-hydroxysteroid Dehydrogenase Activity in the Embryonic Avian Adrenal Gland Grover Charles Ericson Loyola University Chicago Follow this and additional works at: https://ecommons.luc.edu/luc_theses Part of the Medicine and Health Sciences Commons Recommended Citation Ericson, Grover Charles, "The Effects of Exogenous ACTH on 5-3b-hydroxysteroid Dehydrogenase Activity in the Embryonic Avian Adrenal Gland" (1968). Master's Theses. 2264. https://ecommons.luc.edu/luc_theses/2264 This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more information, please contact [email protected]. This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License. Copyright © 1968 Grover Charles Ericson THE EFFECTS OF EXOGENOUS ACTH ON d -JB-HYDROXYSTEROID DEHYDROGENASE ACTIVITY IN THE EMBRYONIC AVIAN ADRENAL GLAND by Grover Charles Ericson A The.is Submitted to the Faculty ot the Graduate School of La.vo1. University in Partial Fulfillment ot the Requirements for the Degree ot Master ot Science February 1968 BIOGRAPHY Grover Charles Ericson was born in Oak Park, D.linois, on February 17. 1941. He •• graduated f'rom the Naperville COIIUlIW1ity High School, Naperville. D.l1nois in June, 19.59. He entered North Central College, Naperville. Illinois, in September, 19.59, and was awarded the Bachelor of Arts degree in June, 1964. While attending North Central College.
    [Show full text]
  • A Thesis Entitled "APPLICATIONS of GAS CHROMATOGRAPHY
    A Thesis entitled "APPLICATIONS OF GAS CHROMATOGRAPHY - MASS SPECTROMETRY IN STEROID CHEMISTRY" Submitted in part fulfilment of the requirements for admittance to the degree of Doctor of Philosophy in The University of Glasgow by T.A. Baillie, B.Sc. University of Glasgow 1973. ProQuest Number: 11017930 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11017930 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere thanks to Dr. C.3.W. Brooks for his guidance and encouragement at all times, and to Professors R.A. Raphael, F.R.S., and G.W. Kirby, for the opportunity to carry out this research. Thanks are also due to my many colleagues for useful discussions, and in particular to Dr. B.S. Middleditch who was associated with me in the work described in Section 3 of this thesis. The work was carried out during the tenure of an S.R.C. Research Studentship, which is gratefully acknowledged. Finally, I would like to thank Miss 3.H.
    [Show full text]
  • United States Patent Office Patented Oct
    3,211,760 United States Patent Office Patented Oct. 12, 1965 2 Furthermore there may be mentioned: 3,211,760 PROCESS FOR THE MANUFACTURE OF A-3:20-dioxo-10-acetoxy-19-norpregnene, 19-NOR-STERODS A-3:20-dioxo-10:17a-diacetoxy-19-norpregnene, Oskar Jeger and Kurt Schaffner, Zurich, Switzerland, A-3-oxo-10-acetoxy-19-norspirostene, and the 6-dehydro assignors to Ciba Corporation, New York, N.Y., a cor derivatives thereof, such as poration of Delaware A-3: 17-dioxo-103-acetoxy-19-norandrostadiene or No Drawing. Filed May 7, 1963, Ser. No. 278,775 A-3:20-dioxo-103:17a-diacetoxy-19-norpregnadiene. Claims priority, application Switzerland, May 11, 1962, 5,736/62 For the reduction according to the invention there are 19 Claims, (C. 260-397.3) O particularly suitable metallic reducing agents, more es pecially those which are capable of removing the 10-sub The present invention provides a new process for the stituent by reduction and at the same time converting the manufacture of 10-unsubstituted 19-norsteroids from A-3-oxo grouping into a A35(10)-enolate; that is to say steriods that contain an esterified hydroxyl group in posi that there are primarily suitable metals of groups I and tion 10. 15 II of the Periodic System, if desired in combination with 19-norsteroids, more especially derivatives of 19-nortes hydrogen donors, for example, alkali or alkaline earth tosterone and of 19-norprogesterone, have become very metals such as sodium, potassium, lithium or calcium, important in recent years as anabolic and gestagenic medic preferably dissolved in liquid ammonia or in an amine aments and as ovulation inhibitors.
    [Show full text]
  • Structural Basis for Human Sterol Isomerase in Cholesterol Biosynthesis and Multidrug Recognition
    ARTICLE https://doi.org/10.1038/s41467-019-10279-w OPEN Structural basis for human sterol isomerase in cholesterol biosynthesis and multidrug recognition Tao Long 1, Abdirahman Hassan 1, Bonne M Thompson2, Jeffrey G McDonald1,2, Jiawei Wang3 & Xiaochun Li 1,4 3-β-hydroxysteroid-Δ8, Δ7-isomerase, known as Emopamil-Binding Protein (EBP), is an endoplasmic reticulum membrane protein involved in cholesterol biosynthesis, autophagy, 1234567890():,; oligodendrocyte formation. The mutation on EBP can cause Conradi-Hunermann syndrome, an inborn error. Interestingly, EBP binds an abundance of structurally diverse pharmacolo- gically active compounds, causing drug resistance. Here, we report two crystal structures of human EBP, one in complex with the anti-breast cancer drug tamoxifen and the other in complex with the cholesterol biosynthesis inhibitor U18666A. EBP adopts an unreported fold involving five transmembrane-helices (TMs) that creates a membrane cavity presenting a pharmacological binding site that accommodates multiple different ligands. The compounds exploit their positively-charged amine group to mimic the carbocationic sterol intermediate. Mutagenesis studies on specific residues abolish the isomerase activity and decrease the multidrug binding capacity. This work reveals the catalytic mechanism of EBP-mediated isomerization in cholesterol biosynthesis and how this protein may act as a multi-drug binder. 1 Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 2 Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. 3 State Key Laboratory of Membrane Biology, School of Life Sciences, Tsinghua University, Beijing 100084, China. 4 Department of Biophysics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
    [Show full text]
  • Evolution of 17Beta-Hydroxysteroid Dehydrogenases and Their Role in Androgen, Estrogen and Retinoid Action
    UC San Diego UC San Diego Previously Published Works Title Evolution of 17beta-Hydroxysteroid Dehydrogenases and Their Role in Androgen, Estrogen and Retinoid Action Permalink https://escholarship.org/uc/item/1md640v5 Journal Molecular and Cellular Endocrinology, 171 Author Baker, Michael E Publication Date 2001 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Molec ular and Cellular Endocrinol ogy vol. 171, pp. 211 -215, 2001. Evolution of 17 -Hydroxysteroid Dehydrogenases and Their Role in Androgen, Estrogen and Retinoid Action Michael E. Baker Department of Medicine, 0823 University of California, San Diego 950 0 Gilman Drive La Jolla, CA 92093 -0823 phone: 858 -534 -8317 fax: 858 -822 -0873 e-mail: [email protected] Abstract. 17 -hydroxysteroid dehydrogenases (17 -HSDs) regulate androgen and estrogen concentrations in mammals. By 1995, four distinct enzymes with 17 -HSD activity had been identified: 17 -HSD -types 1 and 3, which in vivo are NADPH -dependent reductases; 17 -HSD - types 2 and 4, which in vivo are NAD +-dependent oxidases. Since then six additional enzymes with 17 -HSD activity have been isolated from mammal s. With the exception of 17 -HSD –type 5, which belongs to the aldoketo -reductase (AKR) family, these 17 -HSDs belong to the short chain dehydrogenases/reductases (SDR) family. Several 17 -HSDs appear to be examples of convergent evolution. That is, 17 -HSD activity arose several times from different ancestors. Some 17 -HSDs share a common ancestor with retinoid oxido -reductases and have retinol dehydrogenase activity. 17 -HSD -types 2, 6 and 9 appear to have diverged from ancestral retinoid dehydrogenas es early in the evolution of deuterostomes during the Cambrian, about 540 million years ago.
    [Show full text]
  • Nomenclature of Steroids
    Pure&App/. Chern.,Vol. 61, No. 10, pp. 1783-1822,1989. Printed in Great Britain. @ 1989 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE* NOMENCLATURE OF STEROIDS (Recommendations 1989) Prepared for publication by G. P. MOSS Queen Mary College, Mile End Road, London El 4NS, UK *Membership of the Commission (JCBN) during 1987-89 is as follows: Chairman: J. F. G. Vliegenthart (Netherlands); Secretary: A. Cornish-Bowden (UK); Members: J. R. Bull (RSA); M. A. Chester (Sweden); C. LiCbecq (Belgium, representing the IUB Committee of Editors of Biochemical Journals); J. Reedijk (Netherlands); P. Venetianer (Hungary); Associate Members: G. P. Moss (UK); J. C. Rigg (Netherlands). Additional contributors to the formulation of these recommendations: Nomenclature Committee of ZUB(NC-ZUB) (those additional to JCBN): H. Bielka (GDR); C. R. Cantor (USA); H. B. F. Dixon (UK); P. Karlson (FRG); K. L. Loening (USA); W. Saenger (FRG); N. Sharon (Israel); E. J. van Lenten (USA); S. F. Velick (USA); E. C. Webb (Australia). Membership of Expert Panel: P. Karlson (FRG, Convener); J. R. Bull (RSA); K. Engel (FRG); J. Fried (USA); H. W. Kircher (USA); K. L. Loening (USA); G. P. Moss (UK); G. Popjiik (USA); M. R. Uskokovic (USA). Correspondence on these recommendations should be addressed to Dr. G. P. Moss at the above address or to any member of the Commission. Republication of this report is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference together with IUPAC copyright symbol (01989 IUPAC), is printed.
    [Show full text]
  • Control of Steroid, Heme, and Carcinogen Metabolism by Nuclear Pregnane X Receptor and Constitutive Androstane Receptor
    Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor Wen Xie*†‡, Mei-Fei Yeuh‡§, Anna Radominska-Pandya¶, Simrat P. S. Saini*, Yoichi Negishi*, Bobbie Sue Bottroff†, Geraldine Y. Cabrera†, Robert H. Tukey§, and Ronald M. Evans†ʈ *Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213; †Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037; §Laboratory of Environmental Toxicology, Departments of Chemistry, and Biochemistry and Pharmacology, University of California at San Diego, La Jolla, CA 92093; and ¶Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 Contributed by Ronald M. Evans, December 31, 2002 Through a multiplex promoter spanning 218 kb, the phase II UDP- ogens, estrogen, and thyroxin metabolism. Moreover, activation of glucuronosyltransferase 1A (UGT1) gene encodes at least eight dif- PXR in transgenic mice is sufficient to increase levels of UGT ferently regulated mRNAs whose protein products function as the expression and activity, as well as bilirubin and steroid clearance. principal means to eliminate a vast array of steroids, heme metabo- lites, environmental toxins, and drugs. The orphan nuclear receptors Materials and Methods pregnane X receptor (PXR) and constitutive androstane receptor Animals. The generation of VP-hPXR, hPXR (previously known as (CAR) were originally identified as sensors able to respond to numer- VPSXR and SXR) transgenic mice and PXR null mice has been ous environmentally derived foreign compounds (xenobiotics) to described (8). promote detoxification by phase I cytochrome P450 genes. In this report, we show that both receptors can induce specific UGT1A UGT1A1 Promoter Cloning and Site-Directed Mutagenesis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin Et Al
    USOO8486374B2 (12) United States Patent (10) Patent No.: US 8,486,374 B2 Tamarkin et al. (45) Date of Patent: Jul. 16, 2013 (54) HYDROPHILIC, NON-AQUEOUS (56) References Cited PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES U.S. PATENT DOCUMENTS 1,159,250 A 11/1915 Moulton 1,666,684 A 4, 1928 Carstens (75) Inventors: Dov Tamarkin, Maccabim (IL); Meir 1924,972 A 8, 1933 Beckert Eini, Ness Ziona (IL); Doron Friedman, 2,085,733. A T. 1937 Bird Karmei Yosef (IL); Alex Besonov, 2,390,921 A 12, 1945 Clark Rehovot (IL); David Schuz. Moshav 2,524,590 A 10, 1950 Boe Gimzu (IL); Tal Berman, Rishon 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely LeZiyyon (IL); Jorge Danziger, Rishom 2,767,712 A 10, 1956 Waterman LeZion (IL); Rita Keynan, Rehovot (IL); 2.968,628 A 1/1961 Reed Ella Zlatkis, Rehovot (IL) 3,004,894 A 10/1961 Johnson et al. 3,062,715 A 11/1962 Reese et al. 3,067,784. A 12/1962 Gorman (73) Assignee: Foamix Ltd., Rehovot (IL) 3,092.255. A 6, 1963 Hohman 3,092,555 A 6, 1963 Horn 3,141,821 A 7, 1964 Compeau (*) Notice: Subject to any disclaimer, the term of this 3,142,420 A 7/1964 Gawthrop patent is extended or adjusted under 35 3,144,386 A 8/1964 Brightenback U.S.C. 154(b) by 1180 days. 3,149,543 A 9, 1964 Naab 3,154,075 A 10, 1964 Weckesser 3,178,352 A 4, 1965 Erickson (21) Appl.
    [Show full text]